CEVEC is a center of expertise for the production of biopharmaceuticals using a unique human cell-based production system.

CAP-GT is a regulatory endorsed expression platform for scalable viral vector production. CEVEC has successfully developed CAP-GT suspension cell-derived viral packaging cell lines which enable better scale-up and competitive production costs when compared to adherent cell culture systems. CAP-GT suspension cell lines grow to high cell densities and show a broad viral propagation spectrum. Gene therapy vectors such as lentivirus (LV), adenovirus (AV) and adeno-associated virus (AAV) can be produced at industrial scale.

CAP-Go enables the production of proteins previously out of reach representing a significant proportion of the human proteome that is notoriously difficult to express in conventional cell lines such as CHO. The CAP-Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for the highly efficient production of a broad range of difficult to express recombinant proteins with authentic human post-translational modifications or on demand tailor made glycosylation patterns.

Follow CEVEC on LinkedIn.

MANAGEMENT

FRANK UBAGS

With over 35 years of leadership experience, Frank executed major financing and licensing transactions while instigating and driving company growth and turn around strategies. He initiated and executed several major M&A transactions in the Life Science sector, worldwide. Among others, he worked for Rhein Biotech, Kiadis Pharma and Scil Proteins in CEO, CFO and COO positions.

FRANK UBAGS

Chief Executive Officer

DR. NADINE SANDHÖFER

Dr. Nadine Sandhöfer joined CEVEC in 2015. She holds a PhD in human biology with a strong scientific background in tumor biology and in the field of targeted therapies. As a scientist and research manager, Nadine held positions with the Helmholtz Center Munich and the DKFZ Heidelberg. During her position in an ISO certified medical laboratory at the University Hospital Munich, she was trained and certified as quality management representative and internal auditor.

DR. NADINE SANDHÖFER

Director QA and Regulatory Affairs

DR. NICOLE FAUST

Dr. Nicole Faust has extensive management experience in the biotechnology sector. Over the last 18 years she has held scientific management positions with Artemis/Taconic Biosciences, amaxa, Lonza, and CEVEC, engaging in the fields of pharmaceutical models, gene transfer, protein production, and gene therapy. She received her Ph.D. from University of Freiburg and an MBA degree from Educatis University, Switzerland.

DR. NICOLE FAUST

Chief Scientific Officer

DR. NICO SCHEER

Dr. Nico Scheer adds more than 10 years of experience in business development, portfolio and project management, plus licensing and partnering activities in the life science industry as well as a strong scientific background in drug metabolism, molecular biology, and in vitro technologies. He holds a PhD in Molecular Developmental Biology and a PMI certified Project Management Professional (PMP).

DR. NICO SCHEER

Chief Business Officer

BOARD

BART BERGSTEIN

BART BERGSTEIN

Cofounder of Forbion Capital Partners

Former Life Science Venture Capitalist

Christian Leikert

Christian Leikert

Investment Manager

at Creathor Venture

DR. ARISTOTELIS NASTOS

DR. ARISTOTELIS NASTOS

Head of Life Sciences

at NRW Bank Venture Fund

DR. JOACHIM RAUTTER

DR. JOACHIM RAUTTER

Partner at PEPPERMINTVENTURE

PARTNERS / Chairman of the Board

DR. KLAUS ZIMMERMANN

DR. KLAUS ZIMMERMANN

Barrister-at-law

...

Scientific Advisory Board CAP®Go

PROF. DR. JÜRGEN HUBBUCH

PROF. DR. JÜRGEN HUBBUCH

Professor at Karlsruhe Institute of Technology

Head of the Institute of Engineering in Life Section IV: Biomolecular Separation Engineering

PROF. DR. THOMAS NOLL

PROF. DR. THOMAS NOLL

Professor and Chair for Cell Culture Technology

University of Bielefeld

Scientific Advisory Board CAP®GT

PROF. DR. STEFAN KOCHANEK

PROF. DR. STEFAN KOCHANEK

Professor at the University of Ulm and Director of the Department of Gene Therapy

DR. OTTO MERTEN

DR. OTTO MERTEN

Head of Applied Vector Studies

Généthon

INVESTORS

GAT Holding (Switzerland), CEVEC’s Chief Executive Officer and Chief Scientific Officer as well as other private investors are complementing the investor base of CEVEC Pharmaceuticals GmbH